| Literature DB >> 27584694 |
Yudao Shen1, Magdalena M Szewczyk2, Mohammad S Eram2, David Smil2, H Ümit Kaniskan1, Renato Ferreira de Freitas2, Guillermo Senisterra2, Fengling Li2, Matthieu Schapira2,3, Peter J Brown2, Cheryl H Arrowsmith2,4, Dalia Barsyte-Lovejoy2, Jing Liu1, Masoud Vedadi2,3, Jian Jin1.
Abstract
Well-characterized selective inhibitors of protein arginine methyltransferases (PRMTs) are invaluable chemical tools for testing biological and therapeutic hypotheses. Based on 4, a fragment-like inhibitor of type I PRMTs, we conducted structure-activity relationship (SAR) studies and explored three regions of this scaffold. The studies led to the discovery of a potent, selective, and cell-active dual inhibitor of PRMT4 and PRMT6, 17 (MS049). As compared to 4, 17 displayed much improved potency for PRMT4 and PRMT6 in both biochemical and cellular assays. It was selective for PRMT4 and PRMT6 over other PRMTs and a broad range of other epigenetic modifiers and nonepigenetic targets. We also developed 46 (MS049N), which was inactive in biochemical and cellular assays, as a negative control for chemical biology studies. Considering possible overlapping substrate specificity of PRMTs, 17 and 46 are valuable chemical tools for dissecting specific biological functions and dysregulation of PRMT4 and PRMT6 in health and disease.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27584694 PMCID: PMC5063716 DOI: 10.1021/acs.jmedchem.6b01033
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446